Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants
Open Access
- 14 July 2025
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 64 (10) , 1495-1506
Abstract
Background and Objective Mescaline is a classic serotonergic psychedelic with a long history of human use. The present study analyzed the pharmacokinetics, pharmacokinetic-pharmacodynamic relationship, and urinary recovery of oral mescaline hydrochloride. Methods Data from 105 single-dose administrations (100–800 mg) in 49 participants from two phase I trials were analyzed with compartmental pharmacokinetics and pharmacokinetic-pharmacodynamic modeling. A one-compartment model with first-order absorption, elimination, and a lag time was used to describe mescaline plasma concentrations. Acute subjective effects, assessed by visual analog scales (range 0–100%), were modeled using a sigmoid Emax model linked to plasma concentrations via a first-order rate constant (ke0). Results Mescaline showed dose-proportional increases in total exposure and maximal concentrations, with a peak concentration reached within 2.0 h (geometric mean) and a half-life of 3.5 h across all doses. Mean model-predicted onset of “any drug effect” occurred around 1 hour post-dose. Maximum predicted effect intensity and duration increased with dose, from 13% and 2.8 h at 100 mg to 89% and 15 h at 800 mg. Over all conditions, 53% of the dose was excreted into urine unchanged, and 31% was excreted as the main metabolite 3,4,5-trimethoxyphenylacetic acid over 24–30 h. Conclusions These findings provide the first detailed pharmacokinetic-pharmacodynamic characterization of mescaline in humans and indicate an oral bioavailability of at least 53%, limited by first-pass metabolism to 3,4,5-trimethoxyphenylacetic acid, followed by predominant renal elimination of both analytes. Clinical Trial Registration ClinicalTrials.gov identifier: NCT04227756 and NCT04849013.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_185111)
- Mind Medicine
- University of Basel
This publication has 36 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy ParticipantsClinical Pharmacology & Therapeutics, 2022
- Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II StudyBiological Psychiatry, 2022
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderJAMA Psychiatry, 2022
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021
- Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy ParticipantsClinical Pharmacology & Therapeutics, 2020
- Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy SubjectsClinical Pharmacokinetics, 2017
- Phenomenology, Structure, and Dynamic of Psychedelic States2016
- Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dosePsychopharmacology, 2007
- A teratogenic study of chlorpromazine, orphenadrine, perphenazine, and LSD-25 in ratsToxicology and Applied Pharmacology, 1972
- Metabolic fate of mescaline in manPsychopharmacology, 1966